SURGICAL HEMOSTATS, INTERNAL TISSUE SEALANTS, AND ADHESION BARRIERS MARKET ANALYSIS

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Product Type (Hemostats (Thrombin Based, Combination Hemostats, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based), Internal Tissue Sealants (Fibrin Based, Collagen Based, Protein Based, Synthetic Polymer Based), Adhesion Barriers (Film Based, Gel Based, Solution Based)), By Application (Surgical Applications (Cardiovascular Surgeries, Neurological Surgeries, Orthopedic Surgeries, Urological & Gynecological Surgeries, General Surgeries, Reconstructive, and Plastic Surgeries, Others), Trauma Cases), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2023
Code : CMI3721
Pages :171
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market: Key Developments

On November 19, 2021, according to an article published by the Journal of Coloproctology, a study was performed at Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan to check the use of an absorbable adhesion barrier made of oxidized regenerated cellulose (INTERCEED) for temporary diverting ileostomy in minimally invasive rectal surgery. The study was performed on 36 patients who underwent ileostomy. The degree of adhesion formation between the ileal limbs and the rectus abdominis muscles, operating time, and estimated blood loss were significantly reduced in patients treated with INTERCEED compared with those treated by the conventional approach. There were no postoperative complications observed. Hence, use of INTERCEED for diverting ileostomy can contribute to reduced adhesion formation.

On October 19, 2021, Toray Industries Inc., a Japan-based manufacturer of medical devices, and ASKA Pharmaceuticals Co. Ltd., a Japan based pharmaceutical company, announced that they had signed a business collaboration agreement to develop and commercialize an adhesion barrier in Japan. Toray and ASKA jointly developed the product to obtain marketing approval of the product in Japan. According to this agreement, Toray manufactured the Product, as ASKA got exclusive market for the Product in Japan.